Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study

NCT07084259 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

352

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: PCSK9 inhibitor
DRUG: Standard Lipid-Lowering Therapy

Sponsor

Hanyang University Seoul Hospital

Collaborators

[object Object]